On Wednesday, Cathie Wood-led Ark Invest made significant trades involving Tempus AI Inc. and Rocket Lab USA Inc..
The Tempus AI Trade
Ark Invest’s ARK Innovation ETF acquired 29,845 shares of Tempus AI, valued at approximately $1.36 million, based on the closing price of $45.50. This purchase aligns with Ark’s ongoing strategy to bolster its position in innovative technology sectors. Tempus AI recently announced its acquisition of Deep 6 AI, a move expected to enhance its network with over 750 provider site locations and access to more than 30 million patients. This acquisition is anticipated to strengthen Tempus AI’s market presence and capabilities.
Furthermore, Tempus AI’s recent earnings report revealed a revenue miss but an earnings-per-share beat, coupled with strong future guidance. The strategic acquisition of Deep 6 AI and the positive earnings outlook underscore Tempus AI’s potential for growth, making it an attractive investment.
Wood has been loading up on Tempus AI stock in recent days. On Tuesday, Ark purchased $4.29 million worth of stock, while on Monday, amid the tech meltdown, the firm had scooped up stock worth $13.23 million.
The Rocket Lab Trade
Ark Invest also made notable moves involving Rocket Lab. The ARK Autonomous Technology & Robotics ETF and ARK Space Exploration & Innovation ETF collectively sold 41,839 shares of Rocket Lab, valued at approximately $771,092, based on the closing price of $18.43. This sale comes amid Rocket Lab’s recent announcement of being selected by Airbus SE to supply solar panels for 100 OneWeb Low Earth Orbit satellites, a development that has positively impacted Rocket Lab’s stock price.
Additionally, Rocket Lab recently inked a non-binding term sheet to acquire a controlling stake in Mynaric AG for $75 million, with an additional earn-out tied to future revenue targets. This acquisition aims to enhance Rocket Lab’s satellite technology capabilities, further solidifying its position in the aerospace sector.
Other Key Trades:
Sold 9,961 shares of CareDx Inc from ARKG.
Bought 8,890 shares of CRISPR Therapeutics AG for ARKK and 1,781 shares for ARKG.
Bought 15,095 shares of Intellia Therapeutics Inc for ARKK and 3,025 shares for ARKG.
Bought 4,847 shares of AeroVironment Inc for ARKQ and 3,093 shares for ARKX.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。